SG11201913517UA - Improved process for preparing aminopyrimidine derivatives - Google Patents

Improved process for preparing aminopyrimidine derivatives

Info

Publication number
SG11201913517UA
SG11201913517UA SG11201913517UA SG11201913517UA SG11201913517UA SG 11201913517U A SG11201913517U A SG 11201913517UA SG 11201913517U A SG11201913517U A SG 11201913517UA SG 11201913517U A SG11201913517U A SG 11201913517UA SG 11201913517U A SG11201913517U A SG 11201913517UA
Authority
SG
Singapore
Prior art keywords
improved process
aminopyrimidine derivatives
preparing
preparing aminopyrimidine
derivatives
Prior art date
Application number
SG11201913517UA
Other languages
English (en)
Inventor
Sang-Ho Oh
Ja-Heouk Khoo
Jong-Chul Lim
Seong-Ran Lee
Hyun Ju
Woo-Seob Shin
Dae-Gyu Park
su-min Park
Yoon-Ah Hwang
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65040211&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201913517U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of SG11201913517UA publication Critical patent/SG11201913517UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22Tin compounds
    • C07F7/2284Compounds with one or more Sn-N linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)
SG11201913517UA 2017-07-28 2018-07-25 Improved process for preparing aminopyrimidine derivatives SG11201913517UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20170096212 2017-07-28
PCT/KR2018/008379 WO2019022485A1 (en) 2017-07-28 2018-07-25 IMPROVED PROCESS FOR THE PREPARATION OF AMINOPYRIMIDINE DERIVATIVES

Publications (1)

Publication Number Publication Date
SG11201913517UA true SG11201913517UA (en) 2020-02-27

Family

ID=65040211

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201913517UA SG11201913517UA (en) 2017-07-28 2018-07-25 Improved process for preparing aminopyrimidine derivatives

Country Status (31)

Country Link
US (4) US10889578B2 (pt)
EP (1) EP3658552B1 (pt)
JP (2) JP7228562B2 (pt)
KR (1) KR20190013553A (pt)
CN (2) CN111315742B (pt)
AU (2) AU2018308038B2 (pt)
BR (1) BR112020001278A2 (pt)
CA (1) CA3070069C (pt)
CO (1) CO2020000374A2 (pt)
DK (1) DK3658552T3 (pt)
EA (1) EA202090383A1 (pt)
ES (1) ES2962961T3 (pt)
FI (1) FI3658552T3 (pt)
HR (1) HRP20231191T1 (pt)
HU (1) HUE063533T2 (pt)
IL (2) IL271973B (pt)
LT (1) LT3658552T (pt)
MA (1) MA49700B1 (pt)
MD (1) MD3658552T2 (pt)
MX (1) MX2022008743A (pt)
NZ (1) NZ761156A (pt)
PH (1) PH12020500059A1 (pt)
PL (1) PL3658552T3 (pt)
PT (1) PT3658552T (pt)
RS (1) RS64654B1 (pt)
SA (1) SA520411112B1 (pt)
SG (1) SG11201913517UA (pt)
SI (1) SI3658552T1 (pt)
UA (1) UA125317C2 (pt)
WO (1) WO2019022485A1 (pt)
ZA (1) ZA202001250B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20231191T1 (hr) * 2017-07-28 2024-02-02 Yuhan Corporation Postupak za proizvodnju n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida putem reakcije odgovarajućeg amina s 3-halo-propionilkloridom
WO2020230091A1 (en) 2019-05-14 2020-11-19 Janssen Biotech, Inc. Combination therapies with bispecific anti-egfr/c-met antibodies and third generation egfr tyrosine kinase inhibitors
US11850248B2 (en) * 2019-05-14 2023-12-26 Yuhan Corporation Therapies with 3rd generation EGFR tyrosine kinase inhibitors
US11780824B2 (en) * 2020-12-16 2023-10-10 Scinopharm Taiwan, Ltd. Process for preparing osimertinib or a salt thereof

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
RU2309150C2 (ru) 2001-11-27 2007-10-27 Уайт Холдингз Корпорейшн 3-цианохинолины в качестве ингибиторов egf-r и her2 киназ
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
KR20070085433A (ko) 2004-11-24 2007-08-27 노파르티스 아게 Jak 저해제들과 bcr-abl, flt-3, fak 또는raf 키나제 저해제들 중 하나 이상의 조합물
US20060270600A1 (en) 2005-05-26 2006-11-30 Eisuke Mekada Anti-cancer agents
TW200736232A (en) 2006-01-26 2007-10-01 Astrazeneca Ab Pyrimidine derivatives
CL2007003049A1 (es) 2006-10-23 2008-05-16 Cephalon Inc Pharmacopeia Drug Compuestos derivados de 2,4-diaminopirimidina; composicion farmaceutica, utiles para tratar trastornos proliferativos.
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
WO2008124085A2 (en) 2007-04-03 2008-10-16 Exelixis, Inc. Methods of using combinations of mek and jak-2 inhibitors
KR101892989B1 (ko) * 2008-06-27 2018-08-30 셀젠 카르 엘엘씨 헤테로아릴 화합물 및 이의 용도
CA2777762A1 (en) 2009-10-12 2011-04-21 Myrexis, Inc. Amino - pyrimidine compounds as inhibitors of tbk1 and/or ikk epsilon
CN102811619B (zh) 2009-11-13 2015-04-22 金纳斯克公司 激酶抑制剂
ES2629170T3 (es) 2009-12-04 2017-08-07 Senhwa Biosciences, Inc. Pirazolopirimidinas y heterociclos relacionados como inhibidores de CK2
EA022623B1 (ru) 2010-10-06 2016-02-29 ГЛАКСОСМИТКЛАЙН ЭлЭлСи Производные бензимидазола в качестве ингибиторов pi3-киназ
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
RU2591195C2 (ru) 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Замещенные n-(1h-индазол-4-ил) имидазол [1,2-а]пиридин-3- карбоксамидные соединения в качестве ингибиторов рецепторной тирозинкиназы iii типа
ES2900230T3 (es) 2011-07-27 2022-03-16 Astrazeneca Ab Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
US20130165472A1 (en) 2011-12-23 2013-06-27 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
EP3617213A1 (en) 2011-12-30 2020-03-04 Hanmi Pharm. Co., Ltd. Thieno[3,2-d]pyrimidine derivatives having inhibitory activity for protein kinases
CN104860891B (zh) 2014-02-25 2017-06-30 上海海雁医药科技有限公司 芳氨基嘧啶类化合物及其应用以及由其制备的药物组合物和药用组合物
EP3143015B1 (en) 2014-05-13 2019-02-20 ARIAD Pharmaceuticals, Inc. Heteroaryl compounds for kinase inhibition
CN111875585B (zh) 2014-06-12 2023-06-23 上海艾力斯医药科技股份有限公司 一类激酶抑制剂
SG11201701960XA (en) * 2014-10-13 2017-04-27 Yuhan Corp Compounds and compositions for modulating egfr mutant kinase activities
CN104788427B (zh) 2015-02-05 2017-05-31 上海泓博智源医药股份有限公司 3‑(2‑嘧啶氨基)苯基丙烯酰胺类化合物及其应用
AR102263A1 (es) 2015-10-14 2017-02-15 Yuhan Corp Compuestos y composiciones para la modulación de las actividades quinasa del receptor de egf mutante
DE102017212159A1 (de) 2017-07-14 2019-01-17 Krones Aktiengesellschaft Verfahren und Vorrichtung zur Handhabung von Stückgütern, Artikeln und/oder Gebinden
PL3658547T3 (pl) 2017-07-28 2024-01-03 Yuhan Corporation Sposób wytwarzania n-(5-(4-(4-formylo-3-fenylo-1h-pirazol-1-ilo)pirymidyn-2-yloamino)-4-metoksy-2-morfolinofenylo)akrylamidu
HRP20231191T1 (hr) * 2017-07-28 2024-02-02 Yuhan Corporation Postupak za proizvodnju n-(5-((4-(4-((dimetilamino)metil)-3-fenil-1h-pirazol-1-il)pirimidin-2-il)amino)-4-metoksi-2-morfolinofenil)akrilamida putem reakcije odgovarajućeg amina s 3-halo-propionilkloridom
CN108826170A (zh) 2018-06-26 2018-11-16 深圳市远润欣电子有限公司 局部全般照明的模式、控制方法及台灯

Also Published As

Publication number Publication date
CN111315742A (zh) 2020-06-19
PT3658552T (pt) 2023-11-03
CN111315742B (zh) 2023-09-01
RS64654B1 (sr) 2023-10-31
EP3658552A1 (en) 2020-06-03
AU2018308038B2 (en) 2022-02-03
PL3658552T3 (pl) 2024-02-19
US20220281861A1 (en) 2022-09-08
IL271973B (en) 2022-08-01
AU2018308038A1 (en) 2020-01-30
JP2023027091A (ja) 2023-03-01
MA49700A (fr) 2021-03-17
WO2019022485A1 (en) 2019-01-31
JP7228562B2 (ja) 2023-02-24
ZA202001250B (en) 2023-04-26
AU2022202936A1 (en) 2022-05-26
DK3658552T3 (da) 2023-11-20
EA202090383A1 (ru) 2020-06-15
CO2020000374A2 (es) 2020-05-05
EP3658552A4 (en) 2021-06-23
IL292429B1 (en) 2023-05-01
SA520411112B1 (ar) 2022-02-21
HRP20231191T1 (hr) 2024-02-02
IL271973A (en) 2020-02-27
MD3658552T2 (ro) 2024-02-29
FI3658552T3 (fi) 2023-11-16
NZ761156A (en) 2024-01-26
US20200165236A1 (en) 2020-05-28
MX2022008743A (es) 2023-02-02
CN116987112A (zh) 2023-11-03
SI3658552T1 (sl) 2023-11-30
JP2020528440A (ja) 2020-09-24
PH12020500059A1 (en) 2020-09-28
BR112020001278A2 (pt) 2020-07-21
US20230312545A1 (en) 2023-10-05
US20210269427A1 (en) 2021-09-02
CA3070069C (en) 2024-02-20
IL292429B2 (en) 2023-09-01
MA49700B1 (fr) 2023-09-27
US10889578B2 (en) 2021-01-12
UA125317C2 (uk) 2022-02-16
CA3070069A1 (en) 2019-01-31
US11286253B2 (en) 2022-03-29
ES2962961T3 (es) 2024-03-22
EP3658552B1 (en) 2023-09-13
HUE063533T2 (hu) 2024-01-28
IL292429A (en) 2022-06-01
KR20190013553A (ko) 2019-02-11
US11708362B2 (en) 2023-07-25
LT3658552T (lt) 2023-11-27
AU2022202936B2 (en) 2023-04-27

Similar Documents

Publication Publication Date Title
ZA201708142B (en) Process for preparing 4-amino-pyridazines
HUE059158T2 (hu) Eljárás pridopidin elõállítására
IL274439A (en) Process for making Tapinaroff
IL292429B1 (en) An improved process for the preparation of aminopyrimidine derivatives
SI3526229T1 (sl) Postopek za pripravo glukopiranozil-substituiranih benzil-benzenskih derivatov
IL275216A (en) A process for the preparation of anthelmintic 4-aminoquinoline-3-carboxamide
HUE053818T2 (hu) Eljárás HMF elõállítására
IL253877A0 (en) Process for preparing 3-chloro-2-vinylphenylsulfonates
ZA201801650B (en) Process for producing novel 4-benzoazonine derivatives
EP3444253A4 (en) PROCESS FOR PREPARING AD-35
ZA201908452B (en) Improved process for preparing imetelstat
PL3573988T3 (pl) Sposób wytwarzania pochodnych puryny
IL248568B (en) A process for the preparation of dihydroisoxazole derivatives
IL273639A (en) A process for the preparation of pyrrolidine alpha-carboxamide derivatives
IL273695A (en) A process for preparing Spiro histories
IL271512B (en) A method for the preparation of modified 4-aminoindan derivatives
IL253630B (en) A process for the preparation of modified phenylisoxazoline derivatives
SG11201709830YA (en) Process for preparing carbazoles